HypertensionNCT03973710
Effect of Probiotics on Blood Pressure Management
A study testing Lactobacillus paracasei dietary supplement in people with Hypertension, run by Sun Yat-sen University at 1 site in China.
Trial summary
Dysbiosis of gut microbiota has been reported to be involved in the development and progression of hypertension in both humans and animal models. Probiotics have been reported to have ameliorative effects in murine models. However, whether probiotics could help alleviate hypertension in adults remain obscure. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypertension
- What is being tested?
- Lactobacillus paracasei dietary supplement
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteChina
- Study dates
- 3 Jun 2022to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Eligible subjects include men and women 18 to 75 years of age with pre-hypertension who has a systemic blood between 120 and 139 mmHg and/ or a diastolic blood pressure between 80 and 80 mmHg;
- Absence of any diet, dietary supplement and medications that might interfere with blood pressure and gut microbiota, especially antibiotics and probiotics.
Who cannot join
- Any other systemic, metabolic and cardiovascular or cerebrovascular diseases;
- Type 1 diabetes, type 2 diabetes treated with insulin or other medications;
- Acute illness or current evidence of acute or chronic inflammatory or infective diseases;
- Participation in any diet or lifestyle program more than 2 times per week in the latest 3 months prior to recruitment;
- Mental illness rendering them unable to understand the nature, scope, and possible consequences of the study.
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Nutrition and Food Hygiene
Guangzhou, Guangdong, 510080
About this study
Official title: Role of Probiotics in the Prevention of Hypertension
Dysbiosis of gut microbiota has been reported to be involved in the development and progression of hypertension in both humans and animal models. Probiotics have been reported to have ameliorative effects in murine models. However, whether probiotics could help alleviate hypertension in adults remain obscure.
Read the detailed description
Probiotics are live microorganisms that have been associated with multiple health benefits. However, its protective role in adults has long been controversial. This study aims to examine the effect of 12-week probiotics supplementation on the prevention of hypertension in Chinese adults. By understanding the mechanisms by which probiotics exert this beneficial effects, we can better control the rising prevalence of hypertension, which is a major risk factor for cardiovascular diseases.
- Conditions
- Hypertension
- Being tested
- Lactobacillus paracasei dietary supplement, Placebo controls
- Keywords
- Probiotics, Prevention, Hypertension
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lactobacillus paracasei dietary supplementDietary supplement
a commercial probiotic dietary supplement
Placebo controlsDietary supplement
placebo with a similar appearance to probiotics supplement
| Study group | Role | What they receive |
|---|---|---|
| Probiotics group | Experimental | Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations. Receives: Dietary Supplement: Lactobacillus paracasei dietary supplement |
| Placebo group | Placebo comparator | Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations. Receives: Dietary Supplement: Placebo controls |
What is being measured
The primary outcome is the main question the study is designed to answer.
changes of systolic blood pressure
changes of systolic blood pressure
Measured: baseline, 4 weeks, 8 weeks and 12 weeks
changes of diastolic blood pressure
changes of diastolic blood pressure
Measured: baseline, 4 weeks, 8 weeks and 12 weeks
changes of gut microbiota
changes of gut microbiota by metagenomics
Measured: baseline, 4 weeks, 8 weeks and 12 weeks
Secondary outcomes (3)
changes of pulse wave velocity
changes of pulse wave velocity
Measured: baseline and after 12-week intervention
changes of ankle brachial index
changes of ankle brachial index
Measured: baseline and after 12-week intervention
changes of microbial metabolite
changes of microbial metabolite by untargeted metabolomics
Measured: baseline and after 12-week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2019
- Study start3 Jun 2022 (estimated)
- Primary completion31 Mar 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Why it stopped: not enough intervention materials can be provided
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by Sun Yat-sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sun Yat-sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Min Xia, Sun Yat-sen University
- Investigators
- Min Xia, PhD, Principal investigator, Sun Yat-sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03973710
- Sponsor's protocol ID
- ProHealth-2
- Status last verified
- May 2022
- First submitted
- 3 Jun 2019
- Last updated
- 9 May 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of Probiotics in the Prevention of Hypertension
- ClinicalTrials.gov ID
- NCT03973710
- Acronym / sponsor ID
- ProHealth-2
- Conditions
- Hypertension
- Keywords
- Probiotics, Prevention, Hypertension
- Study type
- Interventional
- Recruitment status
- SuspendedReason stopped: not enough intervention materials can be provided
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Sun Yat-sen UniversityUniversity, hospital or other
- Study start
- 3 Jun 2022 (estimated)
- Primary completion
- 31 Mar 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 4 Jun 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dysbiosis of gut microbiota has been reported to be involved in the development and progression of hypertension in both humans and animal models. Probiotics have been reported to have ameliorative effects in murine models. However, whether probiotics could help alleviate hypertension in adults remain obscure.
Detailed description
Probiotics are live microorganisms that have been associated with multiple health benefits. However, its protective role in adults has long been controversial. This study aims to examine the effect of 12-week probiotics supplementation on the prevention of hypertension in Chinese adults. By understanding the mechanisms by which probiotics exert this beneficial effects, we can better control the rising prevalence of hypertension, which is a major risk factor for cardiovascular diseases.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Probiotics group | Experimental | Dietary Supplement: Lactobacillus paracasei dietary supplementParticipants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations. |
| Placebo group | Placebo comparator | Dietary Supplement: Placebo controlsParticipants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Eligible subjects include men and women 18 to 75 years of age with pre-hypertension who has a systemic blood between 120 and 139 mmHg and/ or a diastolic blood pressure between 80 and 80 mmHg;
- Absence of any diet, dietary supplement and medications that might interfere with blood pressure and gut microbiota, especially antibiotics and probiotics.
Key exclusion criteria (5 listed)
- Any other systemic, metabolic and cardiovascular or cerebrovascular diseases;
- Type 1 diabetes, type 2 diabetes treated with insulin or other medications;
- Acute illness or current evidence of acute or chronic inflammatory or infective diseases;
- Participation in any diet or lifestyle program more than 2 times per week in the latest 3 months prior to recruitment;
- Mental illness rendering them unable to understand the nature, scope, and possible consequences of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lactobacillus paracasei dietary supplementa commercial probiotic dietary supplement | Dietary supplement | Probiotics group |
| Placebo controlsplacebo with a similar appearance to probiotics supplement | Dietary supplement | Placebo group |
Primary outcome
changes of systolic blood pressure
Time frame: baseline, 4 weeks, 8 weeks and 12 weeks
changes of systolic blood pressure
changes of diastolic blood pressure
Time frame: baseline, 4 weeks, 8 weeks and 12 weeks
changes of diastolic blood pressure
changes of gut microbiota
Time frame: baseline, 4 weeks, 8 weeks and 12 weeks
changes of gut microbiota by metagenomics
3 secondary outcomes
changes of pulse wave velocity
Time frame: baseline and after 12-week intervention
changes of ankle brachial index
Time frame: baseline and after 12-week intervention
changes of microbial metabolite
Time frame: baseline and after 12-week intervention
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 May 2022.
- Individual participant dataSharing planned: No
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Min Xia, PhD principal investigator
Sun Yat-sen University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lactobacillus paracasei dietary supplement in people with Hypertension, run by Sun Yat-sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 9 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
changes of systolic blood pressure (time frame: baseline, 4 weeks, 8 weeks and 12 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2022.